Daclizumab

Zenapax

25MG/5ML InjectionUnited StatesWithdrawnAuthorised 10 Dec 1997

This page is kept for reference and is not offered to search engines.

In other countries

The same active substances on other registers, the same brand first.

Documents

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Daclizumab

Zenapax

25MG/5ML InjectionUnited StatesWithdrawnAuthorised 10 Dec 1997

Open in the registerAsk Osler about it

This page is kept for reference and is not offered to search engines.

In other countries

The same active substances on other registers, the same brand first.

Documents

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

The official texts, at the regulator.

Register entryFDA

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

U.S. Food and Drug Administration

FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.

Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions · Added 11 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Daclizumab
Strength: 25MG/5ML
Dosage form: Injection
Route: Intravenous
Register: United States (FDA)
Status: Withdrawn
Status in the register: Voluntarily Revoked / Disc
Authorised: 10 Dec 1997
Registration: BLA 103749
Marketing authorisation holder: Hoffmann-La Roche Inc.
Procedure: 351(a)
Supply: Disc